Hims & Hers Health, Inc. (NYSE:HIMS) Receives $38.92 Consensus PT from Analysts

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given an average rating of “Reduce” by the fourteen analysts that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and two have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $38.9167.

HIMS has been the subject of several research reports. Wall Street Zen downgraded shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Hims & Hers Health in a research report on Tuesday.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Irene Becklund sold 8,410 shares of Hims & Hers Health stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $424,705.00. Following the completion of the sale, the insider directly owned 1,418 shares of the company’s stock, valued at approximately $71,609. The trade was a 85.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Oluyemi Okupe sold 11,595 shares of Hims & Hers Health stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $57.72, for a total transaction of $669,263.40. Following the sale, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at approximately $4,053,791.04. This trade represents a 14.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,561,799 shares of company stock worth $80,686,085. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its position in Hims & Hers Health by 1.5% in the second quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock valued at $236,622,000 after acquiring an additional 71,593 shares during the last quarter. Invesco Ltd. lifted its position in Hims & Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock valued at $127,237,000 after acquiring an additional 2,128,587 shares during the last quarter. Northern Trust Corp lifted its position in Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares during the last quarter. Yong Rong HK Asset Management Ltd lifted its position in Hims & Hers Health by 41.2% in the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after acquiring an additional 700,100 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Hims & Hers Health in the first quarter valued at about $58,403,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $54.12 on Friday. The company has a fifty day simple moving average of $50.66 and a two-hundred day simple moving average of $48.33. The company has a market cap of $12.23 billion, a price-to-earnings ratio of 67.65, a price-to-earnings-growth ratio of 3.74 and a beta of 2.25. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. Hims & Hers Health has a 52 week low of $18.33 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business’s revenue was up 72.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.